News

29

Apr, 2019

c4c Consortium selects inaugural Research Portfolio

Tags:

We are delighted to announce the selection of the c4c consortium’s first portfolio of pan-European paediatric studies aimed at advancing the understanding of high priority medicines commonly used in babies, children and young people in Europe. The four inaugural studies will be conducted by academic institutions, in addition to three or four studies by industry partners, covering different diseases and age groups. The selected studies will implement new ways to: • Ensure that the experiences and preferences of children and young people are reflected in clinical trial design and minimise the burden […]

READ MORE

29

Apr, 2019

Immunoglobulin-like Domain of HsFcμR as a Capture Molecule for Detection of Crimean-Congo Hemorrhagic Fever Virus- and Zika Virus-Specific IgM Antibodies

 

Authors: Rackow A, Ehmen C, von Possel R, et al. Published in: Clin Chem. 2019;65(3):451-461. Background The cellular surface molecule HsTOSO/FAIM3/HsFcμR has been identified as an IgM-specific Fc receptor expressed on lymphocytes. Here, we show that its extracellular immunoglobulin-like domain (HsFcμR-Igl) specifically binds to IgM/antigen immune complexes (ICs) and exploit this property for the development of novel detection systems for IgM antibodies directed against Crimean-Congo hemorrhagic fever virus (CCHFV) and Zika virus (ZIKV). Methods His-tagged HsFcμR-Igl was expressed in Escherichia coli and purified by affinity chromatography, oxidative refolding, and size-exclusion chromatography. Specific binding of HsFcμR-Igl to […]

READ MORE

29

Apr, 2019

Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration

 

Authors: Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration. Published in: Lancet HIV. 2019;6(2):e105-e115. Background Estimates of incidence of switching to second-line antiretroviral therapy (ART) among children with HIV are necessary to inform the need for paediatric second-line formulations. We aimed to quantify the cumulative incidence of switching to second-line ART among children in an international cohort collaboration. Methods In this international cohort collaboration study, we pooled individual patient-level data for children younger than 18 years who initiated ART (two or more nucleoside reverse-transcriptase inhibitors [NRTI] plus a non-NRTI [NNRTI] or […]

READ MORE

29

Apr, 2019

Severe haematologic toxicity is rare in high risk HIV-exposed infants receiving combination neonatal prophylaxis.

 

Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord Published in: HIV Med. 2019;20(5):291-307 Objectives Combination neonatal prophylaxis (CNP) is recommended in high‐risk situations for the prevention of mother‐to‐child HIV transmission, although data on its safety are limited. The aim of the study was to identify whether neonatal prophylaxis (NP) type is associated with the risk of severe anaemia or neutropaenia. Methods An individual patient data meta‐analysis was conducted within six European cohorts, in infants at high risk for acquiring HIV infection. Adjusted logistic regression models were used to […]

READ MORE

29

Apr, 2019

Prevalence and clinical outcomes of poor immune response despite virologically suppressive antiretroviral therapy among children and adolescents with HIV in Europe and Thailand: cohort study

 

Authors: Collins IJ; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord Published in: Clin Infect Dis. 2019; 28. pii: ciz253. doi: 10.1093/cid/ciz253. [Epub ahead of print] Background In HIV-positive adults, low CD4 cell counts despite fully suppressed HIV-1 RNA on antiretroviral therapy (ART) have been associated with increased risk of morbidity and mortality. We assessed the prevalence and outcomes of poor immune response (PIR) in children on suppressive ART. Methods Sixteen cohorts from the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) contributed data. Children aged<18 years at ART initiation, with sustained […]

READ MORE

26

Apr, 2019

The use of polymyxins to treat carbapenem resistant infections in neonates and children

 

Authors: Thomas R, Velaphi S, Ellis S, et al. Published in: Expert Opin Pharmacother. 2019;20(4):415-422.  Introduction The incidence of healthcare-associated multidrug resistant bacterial infections, particularly due to carbapenem resistant organisms, has been on the rise globally. Among these are the carbapenem resistant Acinetobacter baumannii and Enterobacteriaceae, which have been responsible for numerous outbreaks in neonatal units. The polymyxins (colistin and polymyxin B) are considered to be the last resort antibiotics for treating such infections. However, pharmacokinetic and pharmacodynamic data on the use of polymyxins in neonates and children are very limited, and there are safety concerns. Areas […]

READ MORE

26

Apr, 2019

Effects of an antimicrobial stewardship intervention on perioperative antibiotic prophylaxis in pediatrics

 

Authors: Donà D, Luise D, La Pergola E, et al. Published in: Antimicrob Resist Infect Control. 2019;8:13.  Purpose This study aims to determine the effectiveness of anAntimicrobial Stewardship Program based on a Clinical Pathway (CP) to improve appropriateness in perioperative antibiotic prophylaxis (PAP). Materials and Methods This pre-post quasi-experimental study was conducted in a 12 month period (six months before and six months after CP implementation), in a tertiary Pediatric Surgical Centre. All patients from 1 month to 15 years of age receiving one or more surgical procedures were eligible for inclusion. PAP was defined […]

READ MORE

26

Apr, 2019

Reactivity of routine HIV antibody tests in children with perinatally acquired HIV-1 in England: cross-sectional analysis

 

Authors: Fidler KJ, Foster C, Lim EJ, et al.; for Collaborative HIV Paediatric Study (CHIPS) Steering Committee Published in: Pediatr Infect Dis J. 2019;38(2):146-148 Abstract We assessed HIV antibody prevalence in children with perinatally acquired HIV in England. Eighteen percent (10/55) of those starting combination antiretroviral therapy <6 months of age were seronegative at median age 9.1 years and had lower viral load at diagnosis and combination antiretroviral therapy start and fewer viral rebounds, than 45 of 55 seropositives. Implications for patient selection for HIV cure research, and interpretation of routine antibody testing, are discussed.

READ MORE

26

Apr, 2019

Accelerated aging in perinatally HIV-infected children: clinical manifestations and pathogenetic mechanisms

 

Authors: Chiappini E, Bianconi M, Dalzini A, et al. Published in: Antimicrob Resist Infect Control. 2019;8:13 Background Premature aging and related diseases have been documented in HIV-infected adults. Data are now emerging also regarding accelerated aging process in HIV-infected children. Methods A narrative review was performed searching studies on PubMed published in English language in 2004-2017, using appropriate key words, including “aging”, “children”, “HIV”, “AIDS”, “immunosenescence”, “pathogenesis”, “clinical conditions”. Results Premature immunosenescence phenotype of B and T cells in HIV-infected children is mediated through immune system activation and chronic inflammation. Ongoing inflammation processes […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities